|Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference|
A live webcast of the presentation will be available on the
Eiger will also host one-on-one meetings with investors.
The company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward a Phase 3 study for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-jefferies-2019-global-healthcare-conference-300858952.html